Further studies are necessary to investigate the effects of EZH2 inhibitors on the tumor microenvironment and their ability to enhance immunotherapy including immune checkpoint blockade in SMARCB1-deficient tumors. The gene discussed is SMARCB1; the disease is neoplasm.